<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01076205</url>
  </required_header>
  <id_info>
    <org_study_id>P11-973</org_study_id>
    <nct_id>NCT01076205</nct_id>
  </id_info>
  <brief_title>Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis</brief_title>
  <acronym>AGIL</acronym>
  <official_title>Long Term Documentation of the Safety and Efficacy as Well as the Effects on Quality of Life and Work Productivity in Patients With Rheumatoid Arthritis Under HUMIRAÂ® (Adalimumab) in Routine Clinical Practice (AGIL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AbbVie (prior sponsor, Abbott)</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AbbVie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The AGIL study was designed to evaluate the effectiveness and safety of adalimumab over 5
      years in routine daily clinical practice in Germany, with a focus on the impact of therapy on
      employment-related outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 12, 2009</start_date>
  <completion_date type="Actual">September 14, 2017</completion_date>
  <primary_completion_date type="Actual">September 14, 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Number of Missed Working Days Due to Sick Leave in the Past 6 Months</measure>
    <time_frame>Baseline and 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Primary effectiveness outcomes related to employment were performed in patients who were employed part- or full-time at baseline. Sick leave days were based on patient recall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With &gt; 5 Missed Working Days Due to Sick Leave in the Past 6 Months</measure>
    <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Primary effectiveness outcomes related to employment were performed in patients who were employed part- or full-time at baseline. Sick leave days were based on patient recall.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment: Absenteeism</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment: Presenteeism</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment: Total Work Productivity Impairment</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Work Productivity and Activity Impairment: Total Activity Impairment</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Work Activity Index (WAI)</measure>
    <time_frame>Baseline and 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The WAI is a tool designed to record the work ability of employees and consists of 7 questions. The modified WAI used in this study included Questions 1, 2, 4, 6, and 7 of the WAI. Question 3, which involves the number of current diseases diagnosed by a physician, was omitted because this parameter was unlikely to reflect change due to treatment. Question 5 (sick leave during the past year) was replaced with the previous question concerning sick leave days.WAI scores range from 7 (worst) to 49 (best).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Disease Activity Score - 28 Joints (DAS28)</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt; 5.1 indicates high disease activity, a DAS28 score &lt; 3.2 indicates low disease activity, and a DAS28 score &lt; 2.6 indicates clinical remission.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Tender Joint Count</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Swollen Joint Count</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Erythrocyte Sedimentation Rate</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in C-reactive Protein</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Health-Assessment Questionnaire-Disability Index (HAQ-DI)</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing, eating, walking, and hygiene. Patients are asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>EuroQol-5 Dimensions (EQ-5D) Scores</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>The EuroQol-5 Dimensions (EQ-5D) is a generic instrument for measuring health-related quality of life. The patient questionnaire consists of two parts. The first part includes statements for the following five areas (dimensions):
agility/mobility
self-care
usual activities
pain, bodily discomfort
anxiety, depression
For each dimension the patient is asked for a three-level assessment of their health on the current day: &quot;no problems&quot; (1), &quot;some problems&quot; (2), &quot;extreme problems&quot; (3).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in Euroqol Visual Analog Scale (VAS)</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>EuroQol-5 Dimensions (EQ-5D): The EQ-5D is a generic instrument for measuring health-related quality of life. The patient questionnaire consists of two parts. The second part is a vertical, thermometer-like, VAS ranging from 0 to 100 that provides a patient-reported assessment of overall health. Patients are asked to mark how good or bad their health is on that day, with 100 meaning &quot;the best health you can imagine&quot; and 0 meaning &quot;the worst health you can imagine.&quot;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Physician Visits in Past 6 Months</measure>
    <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Participants self-reported the number of physician visits they had in the past 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Inpatient Hospitalizations in Past 6 Months</measure>
    <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Participants self-reported the number of hospitalizations they had in the past 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Inpatient Hospitalizations in Past 6 Months</measure>
    <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Participants who had been hospitalized were asked how many days they were hospitalized in the past 6 months.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days With Impairment of Non-Occupational Activities in Past 6 Months</measure>
    <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Patients reported the number of days that sickness affected non-occupational activities in four categories: household, child-rearing/parenting, education, and recreational (free-time). Participants with no impairment were considered to have 0 days.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Morning Stiffness</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Assessment of Pain</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Participants were asked to evaluate their level of pain in the past 7 days on a scale from 0 (no pain) to 10 (unbearable pain).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participant's Assessment of Fatigue</measure>
    <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
    <description>Participants were asked to indicate how much they had suffered from abnormal exhaustion and fatigue during the past 7 days on a scale from 0 (none) to 10 (strongly).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Taking Concomitant RA Medications</measure>
    <time_frame>Baseline to month 60</time_frame>
    <description>Assessment of concomitant medications included disease-modifying antirheumatic drugs (DMARDs) (methotrexate, Leflunomid, sulfasalazine), systemic glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), Cox-2 inhibitors (coxibs), analgesics and others.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Assessment of Adalimumab Therapy</measure>
    <time_frame>Months 3, 6, 12, 24, 36, 48, and 60</time_frame>
    <description>Participants were asked to rate therapy with adalimumab in comparison with other previous therapies according to the following response options:
Considerably better
Better
About the same
Worse
Noticeably worse</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">7229</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <description>Adults with moderate to severe active rheumatoid arthritis (RA) who initiated adalimumab therapy during routine clinical care.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Community sample: Patients with rheumatoid arthritis
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe active rheumatoid arthritis in adults with insufficient response to
             disease-modifying antirheumatic drugs

          -  Inclusive methotrexate

          -  Moderate to severe active rheumatoid arthritis in adults who have not been treated
             with methotrexate before; In case of incompatibility with methotrexate, Humira can be
             used as monotherapy.

        Exclusion Criteria:

          -  Hypersensitivity against the drug or one of the other ingredients

          -  Active tuberculosis or other severe infections (e.g. sepsis and opportunistic
             infections)

          -  Moderate to severe cardiac insufficiency
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henning Kleine, PhD</last_name>
    <role>Study Director</role>
    <affiliation>AbbVie Deutschland GmbH &amp; Co. KG, Medical Department</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <link>
    <url>http://rxabbvie.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>February 24, 2010</study_first_submitted>
  <study_first_submitted_qc>February 24, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 26, 2010</study_first_posted>
  <results_first_submitted>September 10, 2018</results_first_submitted>
  <results_first_submitted_qc>September 10, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">February 7, 2019</results_first_posted>
  <last_update_submitted>September 10, 2018</last_update_submitted>
  <last_update_submitted_qc>September 10, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Work Productivity</keyword>
  <keyword>Long-term Observation</keyword>
  <keyword>Humira</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Rheumatoid Arthritis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan: original</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>October 28, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT01076205/Prot_SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol: amendment</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 6, 2012</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/05/NCT01076205/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Adults with rheumatoid arthritis (RA) were enrolled at 326 clinical centers in Germany and seen during regular visits for routine clinical care.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Adalimumab</title>
          <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7229"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1210"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6019"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Drug Reaction</title>
              <participants_list>
                <participants group_id="P1" count="299"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Effectiveness</title>
              <participants_list>
                <participants group_id="P1" count="1423"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other Reason</title>
              <participants_list>
                <participants group_id="P1" count="1075"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown Reason</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="3151"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The safety set included all enrolled participants who received at least one dose of adalimumab.</population>
      <group_list>
        <group group_id="B1">
          <title>Adalimumab</title>
          <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7229"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Participants with available data</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7165"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Participants with available data</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7176"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5267"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Duration of Disease</title>
          <population>Participants with available data</population>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7039"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9.6" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Number of Missed Work Days in Last 6 Months</title>
          <population>Participants who were employed part-time or full-time</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3887"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19.9" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Work Productivity and Activity Impairment</title>
          <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health. WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
          <population>Participants with available WPAI data; The first 3 scores were assessed in participants who were employed.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <title>Absenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2362"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21.4" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Presenteeism</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="3046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="27.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total work productivity impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2124"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50.9" spread="29.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total activity impairment</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6862"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.9" spread="25.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Work Activity Index</title>
          <description>The WAI is a tool designed to record the work ability of employees and consists of 7 questions. The modified WAI used in this study included Questions 1, 2, 4, 6, and 7 of the WAI. Question 3, which involves the number of current diseases diagnosed by a physician, was omitted because this parameter was unlikely to reflect change due to treatment. Question 5 (sick leave during the past year) was replaced with the previous question concerning sick leave days. WAI scores range from 7 (worst) to 49 (best).</description>
          <population>Participants who were employed part-time or full-time</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="2183"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.1" spread="7.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Disease Activity Score â 28 Joints (DAS28)</title>
          <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt; 5.1 indicates high disease activity, a DAS28 score &lt; 3.2 indicates low disease activity, and a DAS28 score &lt; 2.6 indicates clinical remission.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6132"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.63" spread="1.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Tender Joint Count</title>
          <description>Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.</description>
          <population>Participants with available data</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7.4" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Swollen Joint Count</title>
          <description>Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.</description>
          <population>Participants with available data</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="7111"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5.0" spread="5.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Erythrocyte Sedimentation Rate</title>
          <population>Participants with available data</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6348"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.5" spread="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>C-reactive Protein</title>
          <population>Participants with available data</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6764"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17.3" spread="48.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Health-Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing, eating, walking, and hygiene. Patients are asked about their ability to complete these tasks in the past week on the following scale: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6977"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1.19" spread="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Euroqol Visual Analog Scale (VAS)</title>
          <description>EuroQol-5 Dimensions (EQ-5D) is a generic instrument for measuring health-related quality of life. The VAS is a vertical scale ranging from 0 to 100 that provides a patient-reported assessment of overall health. Patients are asked to mark how good or bad their health is on that day, with 100 meaning &quot;the best health you can imagine&quot; and 0 meaning &quot;the worst health you can imagine.&quot;</description>
          <population>Participants with available data</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="6912"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="52.2" spread="22.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Number of Missed Working Days Due to Sick Leave in the Past 6 Months</title>
        <description>Primary effectiveness outcomes related to employment were performed in patients who were employed part- or full-time at baseline. Sick leave days were based on patient recall.</description>
        <time_frame>Baseline and 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set), with available data at baseline and each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Number of Missed Working Days Due to Sick Leave in the Past 6 Months</title>
          <description>Primary effectiveness outcomes related to employment were performed in patients who were employed part- or full-time at baseline. Sick leave days were based on patient recall.</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set), with available data at baseline and each time point.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2267"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1855"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.4" spread="37.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1290"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="868"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.7" spread="32.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With &gt; 5 Missed Working Days Due to Sick Leave in the Past 6 Months</title>
        <description>Primary effectiveness outcomes related to employment were performed in patients who were employed part- or full-time at baseline. Sick leave days were based on patient recall.</description>
        <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set), with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With &gt; 5 Missed Working Days Due to Sick Leave in the Past 6 Months</title>
          <description>Primary effectiveness outcomes related to employment were performed in patients who were employed part- or full-time at baseline. Sick leave days were based on patient recall.</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set), with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3156"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3156"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2326"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1906"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="890"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="613"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="426"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment: Absenteeism</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WPAI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment: Absenteeism</title>
          <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WPAI data.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2253"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1482"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1220"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="37.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="969"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="38.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="660"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.5" spread="36.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="424"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="34.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="287"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="34.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="200"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.2" spread="40.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment: Presenteeism</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WPAI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment: Presenteeism</title>
          <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WPAI data.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2758"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2157"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.3" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1852"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.8" spread="26.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1513"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.7" spread="28.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1084"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.9" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="717"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="490"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.2" spread="27.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment: Total Work Productivity Impairment</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WPAI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment: Total Work Productivity Impairment</title>
          <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WPAI data.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2026"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1313"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.0" spread="27.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1073"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.4" spread="28.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="851"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.4" spread="30.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="596"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.3" spread="30.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="382"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.8" spread="29.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="261"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.7" spread="31.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="171"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.5" spread="33.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Work Productivity and Activity Impairment: Total Activity Impairment</title>
        <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and with available WPAI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Productivity and Activity Impairment: Total Activity Impairment</title>
          <description>The Work Productivity and Activity Impairment (WPAI) questionnaire for general health is a validated tool in RA consisting of 6 questions, based on patient recall of the previous 7 days. WPAI assesses work time missed due to illness (absenteeism), impairment at work due to health (presenteeism), total work productivity impairment due to health (an aggregate measure of both absenteeism and presenteeism), and total non-occupational activity impairment due to health.
WPAI scores are expressed as impairment percentages, with higher scores indicating worse outcomes.</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and with available WPAI data.</population>
          <units>percent impairment</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3248"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2758"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-11.9" spread="26.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2420"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.8" spread="27.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2007"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.8" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1424"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.3" spread="28.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="970"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.4" spread="29.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="687"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="29.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="509"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="28.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Work Activity Index (WAI)</title>
        <description>The WAI is a tool designed to record the work ability of employees and consists of 7 questions. The modified WAI used in this study included Questions 1, 2, 4, 6, and 7 of the WAI. Question 3, which involves the number of current diseases diagnosed by a physician, was omitted because this parameter was unlikely to reflect change due to treatment. Question 5 (sick leave during the past year) was replaced with the previous question concerning sick leave days.WAI scores range from 7 (worst) to 49 (best).</description>
        <time_frame>Baseline and 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WAI data.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Work Activity Index (WAI)</title>
          <description>The WAI is a tool designed to record the work ability of employees and consists of 7 questions. The modified WAI used in this study included Questions 1, 2, 4, 6, and 7 of the WAI. Question 3, which involves the number of current diseases diagnosed by a physician, was omitted because this parameter was unlikely to reflect change due to treatment. Question 5 (sick leave during the past year) was replaced with the previous question concerning sick leave days.WAI scores range from 7 (worst) to 49 (best).</description>
          <population>Participants who were employed outside of the home, on either a part-time or full-time basis, at baseline (employed patient set) and at each time point, and with available WAI data.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2110"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1908"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.5" spread="5.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1442"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="666"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="452"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="6.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="318"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.0" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Disease Activity Score - 28 Joints (DAS28)</title>
        <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt; 5.1 indicates high disease activity, a DAS28 score &lt; 3.2 indicates low disease activity, and a DAS28 score &lt; 2.6 indicates clinical remission.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Disease Activity Score - 28 Joints (DAS28)</title>
          <description>The DAS28 is a validated index of rheumatoid arthritis disease activity. Twenty-eight tender joint counts, 28 swollen joint counts, erythrocyte sedimentation rate (ESR), and the patient's assessment of global disease activity are included in the DAS28 score. Scores on the DAS28 range from 0 to 10. A DAS28 score &gt; 5.1 indicates high disease activity, a DAS28 score &lt; 3.2 indicates low disease activity, and a DAS28 score &lt; 2.6 indicates clinical remission.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3749"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.34" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3229"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.56" spread="1.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2621"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.71" spread="1.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1818"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.84" spread="1.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1250"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.94" spread="1.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="912"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.01" spread="1.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="650"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.15" spread="1.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Tender Joint Count</title>
        <description>Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Tender Joint Count</title>
          <description>Twenty-eight joints were assessed and classified as tender/not tender by pressure and joint manipulation on physical examination.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.3" spread="6.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.9" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2969"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.3" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.6" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.9" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1040"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.1" spread="6.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="752"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.4" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Swollen Joint Count</title>
        <description>Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Swollen Joint Count</title>
          <description>Twenty-eight joints were assessed and classified as swollen/not swollen by pressure and joint manipulation on physical examination.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>joints</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4280"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.2" spread="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3657"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="5.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2969"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.1" spread="5.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2095"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.4" spread="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1456"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-4.8" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1040"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.0" spread="5.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="752"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.5" spread="6.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Erythrocyte Sedimentation Rate</title>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Erythrocyte Sedimentation Rate</title>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>mm/hr</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3893"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="20.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3321"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.9" spread="20.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2705"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.5" spread="21.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1891"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.0" spread="22.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1299"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.9" spread="22.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="953"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="22.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="673"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.9" spread="22.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in C-reactive Protein</title>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in C-reactive Protein</title>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>mg/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4353"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3858"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.1" spread="45.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3296"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.3" spread="49.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2693"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.5" spread="59.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1918"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.0" spread="64.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1319"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-8.6" spread="65.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="950"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.8" spread="47.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="678"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.8" spread="39.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Health-Assessment Questionnaire-Disability Index (HAQ-DI)</title>
        <description>The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing, eating, walking, and hygiene. Patients are asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Health-Assessment Questionnaire-Disability Index (HAQ-DI)</title>
          <description>The HAQ-DI is a patient-reported assessment of physical function that includes 20 items in eight categories representing a comprehensive set of functional activities, including dressing, eating, walking, and hygiene. Patients are asked about their ability to complete these tasks in the past week using the following categories: without any difficulty (0); with some difficulty (1); with much difficulty (2); and unable to do (3). Scores on each task were summed and averaged to provide an overall score ranging from 0 (best) to 3 (worst), with a higher score representing a high-dependency disability.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4130"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.22" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3537"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.24" spread="0.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2873"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="0.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2014"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1400"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.30" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="992"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.32" spread="0.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="727"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.28" spread="0.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>EuroQol-5 Dimensions (EQ-5D) Scores</title>
        <description>The EuroQol-5 Dimensions (EQ-5D) is a generic instrument for measuring health-related quality of life. The patient questionnaire consists of two parts. The first part includes statements for the following five areas (dimensions):
agility/mobility
self-care
usual activities
pain, bodily discomfort
anxiety, depression
For each dimension the patient is asked for a three-level assessment of their health on the current day: &quot;no problems&quot; (1), &quot;some problems&quot; (2), &quot;extreme problems&quot; (3).</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Month 0 - at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 3</title>
            <description>3 months after enrollment</description>
          </group>
          <group group_id="O3">
            <title>Month 6</title>
            <description>6 months after enrollment</description>
          </group>
          <group group_id="O4">
            <title>Month 12</title>
            <description>12 months after enrollment</description>
          </group>
          <group group_id="O5">
            <title>Month 24</title>
            <description>24 months after enrollment</description>
          </group>
          <group group_id="O6">
            <title>Month 36</title>
            <description>36 months after enrollment</description>
          </group>
          <group group_id="O7">
            <title>Month 48</title>
            <description>48 months after enrollment</description>
          </group>
          <group group_id="O8">
            <title>Month 60</title>
            <description>60 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>EuroQol-5 Dimensions (EQ-5D) Scores</title>
          <description>The EuroQol-5 Dimensions (EQ-5D) is a generic instrument for measuring health-related quality of life. The patient questionnaire consists of two parts. The first part includes statements for the following five areas (dimensions):
agility/mobility
self-care
usual activities
pain, bodily discomfort
anxiety, depression
For each dimension the patient is asked for a three-level assessment of their health on the current day: &quot;no problems&quot; (1), &quot;some problems&quot; (2), &quot;extreme problems&quot; (3).</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4400"/>
                <count group_id="O2" value="4118"/>
                <count group_id="O3" value="3524"/>
                <count group_id="O4" value="2856"/>
                <count group_id="O5" value="2020"/>
                <count group_id="O6" value="1401"/>
                <count group_id="O7" value="992"/>
                <count group_id="O8" value="732"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Mobility</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4398"/>
                    <count group_id="O2" value="4118"/>
                    <count group_id="O3" value="3524"/>
                    <count group_id="O4" value="2856"/>
                    <count group_id="O5" value="2020"/>
                    <count group_id="O6" value="1401"/>
                    <count group_id="O7" value="992"/>
                    <count group_id="O8" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1662"/>
                    <measurement group_id="O2" value="2072"/>
                    <measurement group_id="O3" value="1937"/>
                    <measurement group_id="O4" value="1644"/>
                    <measurement group_id="O5" value="1190"/>
                    <measurement group_id="O6" value="843"/>
                    <measurement group_id="O7" value="614"/>
                    <measurement group_id="O8" value="447"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2728"/>
                    <measurement group_id="O2" value="2034"/>
                    <measurement group_id="O3" value="1575"/>
                    <measurement group_id="O4" value="1200"/>
                    <measurement group_id="O5" value="824"/>
                    <measurement group_id="O6" value="554"/>
                    <measurement group_id="O7" value="376"/>
                    <measurement group_id="O8" value="282"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="6"/>
                    <measurement group_id="O6" value="4"/>
                    <measurement group_id="O7" value="2"/>
                    <measurement group_id="O8" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Self-care</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4394"/>
                    <count group_id="O2" value="4116"/>
                    <count group_id="O3" value="3523"/>
                    <count group_id="O4" value="2856"/>
                    <count group_id="O5" value="2020"/>
                    <count group_id="O6" value="1401"/>
                    <count group_id="O7" value="992"/>
                    <count group_id="O8" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2599"/>
                    <measurement group_id="O2" value="2792"/>
                    <measurement group_id="O3" value="2476"/>
                    <measurement group_id="O4" value="2088"/>
                    <measurement group_id="O5" value="1484"/>
                    <measurement group_id="O6" value="1038"/>
                    <measurement group_id="O7" value="729"/>
                    <measurement group_id="O8" value="506"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1680"/>
                    <measurement group_id="O2" value="1226"/>
                    <measurement group_id="O3" value="972"/>
                    <measurement group_id="O4" value="706"/>
                    <measurement group_id="O5" value="503"/>
                    <measurement group_id="O6" value="338"/>
                    <measurement group_id="O7" value="243"/>
                    <measurement group_id="O8" value="208"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="115"/>
                    <measurement group_id="O2" value="98"/>
                    <measurement group_id="O3" value="75"/>
                    <measurement group_id="O4" value="62"/>
                    <measurement group_id="O5" value="33"/>
                    <measurement group_id="O6" value="25"/>
                    <measurement group_id="O7" value="20"/>
                    <measurement group_id="O8" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Usual activities</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4395"/>
                    <count group_id="O2" value="4116"/>
                    <count group_id="O3" value="3523"/>
                    <count group_id="O4" value="2856"/>
                    <count group_id="O5" value="2020"/>
                    <count group_id="O6" value="1401"/>
                    <count group_id="O7" value="992"/>
                    <count group_id="O8" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="953"/>
                    <measurement group_id="O2" value="1463"/>
                    <measurement group_id="O3" value="1431"/>
                    <measurement group_id="O4" value="1303"/>
                    <measurement group_id="O5" value="958"/>
                    <measurement group_id="O6" value="677"/>
                    <measurement group_id="O7" value="503"/>
                    <measurement group_id="O8" value="353"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="3236"/>
                    <measurement group_id="O2" value="2511"/>
                    <measurement group_id="O3" value="1989"/>
                    <measurement group_id="O4" value="1455"/>
                    <measurement group_id="O5" value="1015"/>
                    <measurement group_id="O6" value="696"/>
                    <measurement group_id="O7" value="464"/>
                    <measurement group_id="O8" value="362"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="206"/>
                    <measurement group_id="O2" value="142"/>
                    <measurement group_id="O3" value="103"/>
                    <measurement group_id="O4" value="98"/>
                    <measurement group_id="O5" value="47"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="25"/>
                    <measurement group_id="O8" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain/discomfort</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4400"/>
                    <count group_id="O2" value="4118"/>
                    <count group_id="O3" value="3524"/>
                    <count group_id="O4" value="2856"/>
                    <count group_id="O5" value="2020"/>
                    <count group_id="O6" value="1401"/>
                    <count group_id="O7" value="992"/>
                    <count group_id="O8" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="147"/>
                    <measurement group_id="O2" value="585"/>
                    <measurement group_id="O3" value="587"/>
                    <measurement group_id="O4" value="582"/>
                    <measurement group_id="O5" value="478"/>
                    <measurement group_id="O6" value="383"/>
                    <measurement group_id="O7" value="298"/>
                    <measurement group_id="O8" value="225"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2965"/>
                    <measurement group_id="O2" value="2932"/>
                    <measurement group_id="O3" value="2508"/>
                    <measurement group_id="O4" value="1989"/>
                    <measurement group_id="O5" value="1381"/>
                    <measurement group_id="O6" value="917"/>
                    <measurement group_id="O7" value="631"/>
                    <measurement group_id="O8" value="461"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1288"/>
                    <measurement group_id="O2" value="601"/>
                    <measurement group_id="O3" value="429"/>
                    <measurement group_id="O4" value="285"/>
                    <measurement group_id="O5" value="161"/>
                    <measurement group_id="O6" value="101"/>
                    <measurement group_id="O7" value="63"/>
                    <measurement group_id="O8" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anxiety/depression</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4395"/>
                    <count group_id="O2" value="4116"/>
                    <count group_id="O3" value="3523"/>
                    <count group_id="O4" value="2854"/>
                    <count group_id="O5" value="2020"/>
                    <count group_id="O6" value="1400"/>
                    <count group_id="O7" value="992"/>
                    <count group_id="O8" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>No problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="2159"/>
                    <measurement group_id="O2" value="2328"/>
                    <measurement group_id="O3" value="2141"/>
                    <measurement group_id="O4" value="1791"/>
                    <measurement group_id="O5" value="1349"/>
                    <measurement group_id="O6" value="977"/>
                    <measurement group_id="O7" value="705"/>
                    <measurement group_id="O8" value="526"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Some problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="1961"/>
                    <measurement group_id="O2" value="1601"/>
                    <measurement group_id="O3" value="1238"/>
                    <measurement group_id="O4" value="956"/>
                    <measurement group_id="O5" value="607"/>
                    <measurement group_id="O6" value="395"/>
                    <measurement group_id="O7" value="265"/>
                    <measurement group_id="O8" value="190"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Extreme problems</title>
                  <measurement_list>
                    <measurement group_id="O1" value="275"/>
                    <measurement group_id="O2" value="187"/>
                    <measurement group_id="O3" value="144"/>
                    <measurement group_id="O4" value="107"/>
                    <measurement group_id="O5" value="64"/>
                    <measurement group_id="O6" value="28"/>
                    <measurement group_id="O7" value="22"/>
                    <measurement group_id="O8" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Euroqol Visual Analog Scale (VAS)</title>
        <description>EuroQol-5 Dimensions (EQ-5D): The EQ-5D is a generic instrument for measuring health-related quality of life. The patient questionnaire consists of two parts. The second part is a vertical, thermometer-like, VAS ranging from 0 to 100 that provides a patient-reported assessment of overall health. Patients are asked to mark how good or bad their health is on that day, with 100 meaning &quot;the best health you can imagine&quot; and 0 meaning &quot;the worst health you can imagine.&quot;</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Euroqol Visual Analog Scale (VAS)</title>
          <description>EuroQol-5 Dimensions (EQ-5D): The EQ-5D is a generic instrument for measuring health-related quality of life. The patient questionnaire consists of two parts. The second part is a vertical, thermometer-like, VAS ranging from 0 to 100 that provides a patient-reported assessment of overall health. Patients are asked to mark how good or bad their health is on that day, with 100 meaning &quot;the best health you can imagine&quot; and 0 meaning &quot;the worst health you can imagine.&quot;</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4405"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4073"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.0" spread="24.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3480"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.7" spread="24.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2815"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.9" spread="25.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1990"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1393"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="986"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.8" spread="25.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="725"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.9" spread="25.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Physician Visits in Past 6 Months</title>
        <description>Participants self-reported the number of physician visits they had in the past 6 months.</description>
        <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Month 0 - at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 6</title>
            <description>6 months after enrollment</description>
          </group>
          <group group_id="O3">
            <title>Month 12</title>
            <description>12 months after enrollment</description>
          </group>
          <group group_id="O4">
            <title>Month 24</title>
            <description>24 months after enrollment</description>
          </group>
          <group group_id="O5">
            <title>Month 36</title>
            <description>36 months after enrollment</description>
          </group>
          <group group_id="O6">
            <title>Month 48</title>
            <description>48 months after enrollment</description>
          </group>
          <group group_id="O7">
            <title>Month 60</title>
            <description>60 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Physician Visits in Past 6 Months</title>
          <description>Participants self-reported the number of physician visits they had in the past 6 months.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>visits</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4344"/>
                <count group_id="O2" value="3408"/>
                <count group_id="O3" value="2774"/>
                <count group_id="O4" value="1946"/>
                <count group_id="O5" value="1357"/>
                <count group_id="O6" value="960"/>
                <count group_id="O7" value="703"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Rheumatologist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="3.1"/>
                    <measurement group_id="O2" value="2.5" spread="2.7"/>
                    <measurement group_id="O3" value="2.2" spread="2.0"/>
                    <measurement group_id="O4" value="1.9" spread="1.5"/>
                    <measurement group_id="O5" value="1.8" spread="1.4"/>
                    <measurement group_id="O6" value="1.9" spread="1.4"/>
                    <measurement group_id="O7" value="1.8" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>General practitioner</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="4.6"/>
                    <measurement group_id="O2" value="2.9" spread="4.4"/>
                    <measurement group_id="O3" value="2.6" spread="3.2"/>
                    <measurement group_id="O4" value="2.1" spread="2.5"/>
                    <measurement group_id="O5" value="2.1" spread="3.0"/>
                    <measurement group_id="O6" value="1.9" spread="2.4"/>
                    <measurement group_id="O7" value="1.8" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Orthopedic specialist</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="2.2"/>
                    <measurement group_id="O2" value="0.6" spread="1.9"/>
                    <measurement group_id="O3" value="0.7" spread="1.6"/>
                    <measurement group_id="O4" value="0.5" spread="1.3"/>
                    <measurement group_id="O5" value="0.5" spread="1.3"/>
                    <measurement group_id="O6" value="0.5" spread="1.0"/>
                    <measurement group_id="O7" value="0.5" spread="1.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other specialists</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.2" spread="2.4"/>
                    <measurement group_id="O2" value="0.9" spread="1.8"/>
                    <measurement group_id="O3" value="0.9" spread="1.8"/>
                    <measurement group_id="O4" value="0.8" spread="1.4"/>
                    <measurement group_id="O5" value="0.8" spread="1.5"/>
                    <measurement group_id="O6" value="0.8" spread="1.5"/>
                    <measurement group_id="O7" value="0.8" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Inpatient Hospitalizations in Past 6 Months</title>
        <description>Participants self-reported the number of hospitalizations they had in the past 6 months.</description>
        <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Inpatient Hospitalizations in Past 6 Months</title>
          <description>Participants self-reported the number of hospitalizations they had in the past 6 months.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>hospitalizations</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2774"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.2" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1946"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="960"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="703"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Inpatient Hospitalizations in Past 6 Months</title>
        <description>Participants who had been hospitalized were asked how many days they were hospitalized in the past 6 months.</description>
        <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Inpatient Hospitalizations in Past 6 Months</title>
          <description>Participants who had been hospitalized were asked how many days they were hospitalized in the past 6 months.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4344"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4344"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.3" spread="7.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3408"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2774"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1946"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="960"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="703"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days With Impairment of Non-Occupational Activities in Past 6 Months</title>
        <description>Patients reported the number of days that sickness affected non-occupational activities in four categories: household, child-rearing/parenting, education, and recreational (free-time). Participants with no impairment were considered to have 0 days.</description>
        <time_frame>Baseline, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Month 0 - at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 6</title>
            <description>6 months after enrollment</description>
          </group>
          <group group_id="O3">
            <title>Month 12</title>
            <description>12 months after enrollment</description>
          </group>
          <group group_id="O4">
            <title>Month 24</title>
            <description>24 months after enrollment</description>
          </group>
          <group group_id="O5">
            <title>Month 36</title>
            <description>36 months after enrollment</description>
          </group>
          <group group_id="O6">
            <title>Month 48</title>
            <description>48 months after enrollment</description>
          </group>
          <group group_id="O7">
            <title>Month 60</title>
            <description>60 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days With Impairment of Non-Occupational Activities in Past 6 Months</title>
          <description>Patients reported the number of days that sickness affected non-occupational activities in four categories: household, child-rearing/parenting, education, and recreational (free-time). Participants with no impairment were considered to have 0 days.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3368"/>
                <count group_id="O2" value="2666"/>
                <count group_id="O3" value="2199"/>
                <count group_id="O4" value="1572"/>
                <count group_id="O5" value="1093"/>
                <count group_id="O6" value="784"/>
                <count group_id="O7" value="574"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Household</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3368"/>
                    <count group_id="O2" value="2666"/>
                    <count group_id="O3" value="2199"/>
                    <count group_id="O4" value="1572"/>
                    <count group_id="O5" value="1093"/>
                    <count group_id="O6" value="784"/>
                    <count group_id="O7" value="574"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56.9" spread="64.3"/>
                    <measurement group_id="O2" value="27.7" spread="50.6"/>
                    <measurement group_id="O3" value="22.4" spread="46.1"/>
                    <measurement group_id="O4" value="20.6" spread="46.3"/>
                    <measurement group_id="O5" value="18.2" spread="43.7"/>
                    <measurement group_id="O6" value="19.2" spread="46.1"/>
                    <measurement group_id="O7" value="16.1" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Child-rearing/parenting</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1220"/>
                    <count group_id="O2" value="1068"/>
                    <count group_id="O3" value="896"/>
                    <count group_id="O4" value="654"/>
                    <count group_id="O5" value="435"/>
                    <count group_id="O6" value="300"/>
                    <count group_id="O7" value="195"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.1" spread="41.6"/>
                    <measurement group_id="O2" value="4.7" spread="23.1"/>
                    <measurement group_id="O3" value="3.1" spread="18.1"/>
                    <measurement group_id="O4" value="2.8" spread="18.4"/>
                    <measurement group_id="O5" value="1.9" spread="13.6"/>
                    <measurement group_id="O6" value="3.0" spread="19.7"/>
                    <measurement group_id="O7" value="1.6" spread="8.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Educational</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="975"/>
                    <count group_id="O2" value="887"/>
                    <count group_id="O3" value="750"/>
                    <count group_id="O4" value="558"/>
                    <count group_id="O5" value="379"/>
                    <count group_id="O6" value="257"/>
                    <count group_id="O7" value="168"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.3" spread="31.6"/>
                    <measurement group_id="O2" value="2.5" spread="17.1"/>
                    <measurement group_id="O3" value="1.6" spread="13.3"/>
                    <measurement group_id="O4" value="1.1" spread="10.1"/>
                    <measurement group_id="O5" value="1.0" spread="10.1"/>
                    <measurement group_id="O6" value="0.9" spread="11.5"/>
                    <measurement group_id="O7" value="1.4" spread="12.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Recreational</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3101"/>
                    <count group_id="O2" value="2467"/>
                    <count group_id="O3" value="2000"/>
                    <count group_id="O4" value="1426"/>
                    <count group_id="O5" value="1016"/>
                    <count group_id="O6" value="728"/>
                    <count group_id="O7" value="532"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.1" spread="65.6"/>
                    <measurement group_id="O2" value="28.3" spread="50.9"/>
                    <measurement group_id="O3" value="23.0" spread="47.4"/>
                    <measurement group_id="O4" value="19.5" spread="45.0"/>
                    <measurement group_id="O5" value="18.5" spread="44.9"/>
                    <measurement group_id="O6" value="19.1" spread="46.0"/>
                    <measurement group_id="O7" value="16.3" spread="41.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Morning Stiffness</title>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Morning Stiffness</title>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>minutes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4370"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4370"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65.3" spread="72.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4222"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.6" spread="55.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3617"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.4" spread="44.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2931"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.2" spread="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2070"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.9" spread="39.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1439"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.0" spread="41.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1034"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" spread="29.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="743"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.2" spread="32.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant's Assessment of Pain</title>
        <description>Participants were asked to evaluate their level of pain in the past 7 days on a scale from 0 (no pain) to 10 (unbearable pain).</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Assessment of Pain</title>
          <description>Participants were asked to evaluate their level of pain in the past 7 days on a scale from 0 (no pain) to 10 (unbearable pain).</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4455"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4455"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4178"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3582"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2901"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2045"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.7" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1415"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1004"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="730"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.3" spread="2.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participant's Assessment of Fatigue</title>
        <description>Participants were asked to indicate how much they had suffered from abnormal exhaustion and fatigue during the past 7 days on a scale from 0 (none) to 10 (strongly).</description>
        <time_frame>Baseline and 3, 6, 12, 24, 36, 48, and 60 months</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Adalimumab</title>
            <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
          </group>
        </group_list>
        <measure>
          <title>Participant's Assessment of Fatigue</title>
          <description>Participants were asked to indicate how much they had suffered from abnormal exhaustion and fatigue during the past 7 days on a scale from 0 (none) to 10 (strongly).</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), and with available data at each time point.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4449"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4449"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 3</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4180"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 6</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3580"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.2" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2901"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 24</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="2046"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 36</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1418"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 48</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="1005"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.5" spread="2.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 60</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="732"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Taking Concomitant RA Medications</title>
        <description>Assessment of concomitant medications included disease-modifying antirheumatic drugs (DMARDs) (methotrexate, Leflunomid, sulfasalazine), systemic glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), Cox-2 inhibitors (coxibs), analgesics and others.</description>
        <time_frame>Baseline to month 60</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set).</population>
        <group_list>
          <group group_id="O1">
            <title>Baseline</title>
            <description>Month 0 - at enrollment</description>
          </group>
          <group group_id="O2">
            <title>Any Visit</title>
            <description>From baseline to month 60</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Taking Concomitant RA Medications</title>
          <description>Assessment of concomitant medications included disease-modifying antirheumatic drugs (DMARDs) (methotrexate, Leflunomid, sulfasalazine), systemic glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs), Cox-2 inhibitors (coxibs), analgesics and others.</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set).</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4466"/>
                <count group_id="O2" value="4466"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Methotrexate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.4"/>
                    <measurement group_id="O2" value="58.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leflunomide</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.0"/>
                    <measurement group_id="O2" value="13.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sulfasalazine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6"/>
                    <measurement group_id="O2" value="4.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Analgesics</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.9"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NSAIDs or coxibs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.1"/>
                    <measurement group_id="O2" value="24.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic glucocorticoids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.1"/>
                    <measurement group_id="O2" value="73.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8"/>
                    <measurement group_id="O2" value="9.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Assessment of Adalimumab Therapy</title>
        <description>Participants were asked to rate therapy with adalimumab in comparison with other previous therapies according to the following response options:
Considerably better
Better
About the same
Worse
Noticeably worse</description>
        <time_frame>Months 3, 6, 12, 24, 36, 48, and 60</time_frame>
        <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), with available data at each time point.</population>
        <group_list>
          <group group_id="O1">
            <title>Month 3</title>
            <description>3 months after enrollment</description>
          </group>
          <group group_id="O2">
            <title>Month 6</title>
            <description>6 months after enrollment</description>
          </group>
          <group group_id="O3">
            <title>Month 12</title>
            <description>12 months after enrollment</description>
          </group>
          <group group_id="O4">
            <title>Month 24</title>
            <description>24 months after enrollment</description>
          </group>
          <group group_id="O5">
            <title>Month 36</title>
            <description>36 months after enrollment</description>
          </group>
          <group group_id="O6">
            <title>Month 48</title>
            <description>48 months after enrollment</description>
          </group>
          <group group_id="O7">
            <title>Month 60</title>
            <description>60 months after enrollment</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Assessment of Adalimumab Therapy</title>
          <description>Participants were asked to rate therapy with adalimumab in comparison with other previous therapies according to the following response options:
Considerably better
Better
About the same
Worse
Noticeably worse</description>
          <population>Participants with sufficient data to evaluate clinical outcomes and baseline disease activity high enough to evaluate effectiveness (full analysis set), with available data at each time point.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="4007"/>
                <count group_id="O2" value="3452"/>
                <count group_id="O3" value="2814"/>
                <count group_id="O4" value="1983"/>
                <count group_id="O5" value="1366"/>
                <count group_id="O6" value="971"/>
                <count group_id="O7" value="716"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Considerably better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35.6"/>
                    <measurement group_id="O2" value="39.6"/>
                    <measurement group_id="O3" value="46.3"/>
                    <measurement group_id="O4" value="51.6"/>
                    <measurement group_id="O5" value="51.5"/>
                    <measurement group_id="O6" value="55.5"/>
                    <measurement group_id="O7" value="53.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Better</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36.6"/>
                    <measurement group_id="O2" value="39.7"/>
                    <measurement group_id="O3" value="37.3"/>
                    <measurement group_id="O4" value="37.1"/>
                    <measurement group_id="O5" value="40.4"/>
                    <measurement group_id="O6" value="38.1"/>
                    <measurement group_id="O7" value="38.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>About the same</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.2"/>
                    <measurement group_id="O2" value="14.9"/>
                    <measurement group_id="O3" value="12.2"/>
                    <measurement group_id="O4" value="9.1"/>
                    <measurement group_id="O5" value="6.7"/>
                    <measurement group_id="O6" value="5.6"/>
                    <measurement group_id="O7" value="5.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.9"/>
                    <measurement group_id="O2" value="5.0"/>
                    <measurement group_id="O3" value="3.8"/>
                    <measurement group_id="O4" value="1.9"/>
                    <measurement group_id="O5" value="1.3"/>
                    <measurement group_id="O6" value="0.5"/>
                    <measurement group_id="O7" value="1.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Noticeably worse</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6"/>
                    <measurement group_id="O2" value="0.9"/>
                    <measurement group_id="O3" value="0.4"/>
                    <measurement group_id="O4" value="0.3"/>
                    <measurement group_id="O5" value="0.1"/>
                    <measurement group_id="O6" value="0.3"/>
                    <measurement group_id="O7" value="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>60 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Adalimumab</title>
          <description>Participants with moderate to severe active rheumatoid arthritis who initiated adalimumab therapy during routine clinical care.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA v20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="932" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Leukocytosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Agranulocytosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bicytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Erythropenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypochromic anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aortic valve stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Left ventricular failure</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sinus node dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sinus tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Adams-Stokes syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aortic valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypertensive heart disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mitral valve incompetence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Stress cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Supraventricular tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tachycardia induced cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ventricular extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ventricular fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wolff-Parkinson-White syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Developmental hip dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hereditary neuropathic amyloidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Sudden hearing loss</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vertigo positional</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Adrenocortical insufficiency acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Eye disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Eye haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Iritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ophthalmic vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Retinal detachment</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Colitis microscopic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diverticular perforation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastritis erosive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Colitis ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Crohn's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Femoral hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gingival recession</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intestinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Leukoplakia oral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatic duct stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatic mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rectal polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Salivary gland pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ulcerative gastritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Umbilical hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Unevaluable event</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Complication associated with device</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Impaired healing</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Drug ineffective</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Perforated ulcer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>No adverse event</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Condition aggravated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>General physical health deterioration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Adverse drug reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Drug interaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Exercise tolerance decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Injection site pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Injection site reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Injection site warmth</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Multiple organ dysfunction syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Precancerous mucosal lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Biliary cirrhosis primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholecystitis chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gallbladder perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hepatic cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hepatitis cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Liver disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Immunosuppression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sarcoidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Postoperative wound infection</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abscess limb</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Device related infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Endocarditis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastroenteritis norovirus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intervertebral discitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Septic shock</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound infection</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Appendicitis perforated</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Escherichia sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infectious colitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infectious pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lymph node tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pertussis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Soft tissue infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vestibular neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abscess neck</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abscess soft tissue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acne pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Atypical pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchiolitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchitis bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bursitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Candida infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Candida pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholangitis infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Clostridial infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diabetic gangrene</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Disseminated tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Emphysematous cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Endocarditis staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Escherichia urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gallbladder empyema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Genital candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Herpes ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Herpes simplex encephalitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infected seroma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infection susceptibility increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Keratouveitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Liver abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lymphangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Meningoencephalitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mycobacterium marinum infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Necrotising fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peritoneal abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumonia escherichia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumonia fungal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumonia legionella</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumonia necrotising</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pneumonia viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Poliomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Purulence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pyonephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Salmonellosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Septic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Staphylococcal sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Superinfection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Testicular abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tuberculosis gastrointestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tuberculosis of genitourinary system</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tuberculosis of intrathoracic lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tuberculous pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound infection bacterial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Femoral neck fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Humerus fracture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lumbar vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Accident at work</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fracture displacement</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thoracic vertebral fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Accident at home</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pelvic fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Post procedural complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Post procedural fistula</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Subarachnoid haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wrist fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Clavicle fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fibula fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fractured ischium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ilium fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Kidney rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Limb crushing injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Limb traumatic amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Multiple injuries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nerve injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatic duct rupture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Soft tissue injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Stab wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Suture related complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Arthroscopy</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchoscopy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Biopsy bone marrow</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Biopsy liver</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Computerised tomogram thorax abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Double stranded DNA antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Angiogram peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Antinuclear antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arteriogram coronary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Autoantibody test</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Biopsy lymph gland</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Blood bactericidal activity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Blood calcium</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Catheterisation cardiac</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Colonoscopy normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>DNA antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ejection fraction decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Emergency care examination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Endoscopic retrograde cholangiopancreatography</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Endoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Epstein-Barr virus antibody positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fibrin D dimer increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haematocrit decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haemoglobin decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Heart rate irregular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Laboratory test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Laparoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mediastinoscopy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mycobacterium tuberculosis complex test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neurological examination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neutrophil count decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Proteus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Red blood cell sedimentation rate increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Staphylococcus test positive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Transaminases abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ultrasound abdomen abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound healing normal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Shock hypoglycaemic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lumbar spinal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Synovitis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acquired claw toe</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteoporotic fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal column stenosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lupus-like syndrome</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spondylolisthesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Facet joint syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal instability</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ankle impingement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthritis reactive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bursal haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chondromalacia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Compartment syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Felty's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fibromyalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hip deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint destruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ligament pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Meniscal degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Polyarthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>SAPHO syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sjogren's syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spondyloarthropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Synovial disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tenosynovitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tenosynovitis stenosans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vertebral foraminal stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wrist deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer female</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bladder cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Squamous cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Metastases to bone</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>B-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neuroma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ovarian cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Plasma cell myeloma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Atypical fibroxanthoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Benign cardiac neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bladder neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bowen's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Brain neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Brain neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Breast neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchial neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholangiocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chronic lymphocytic leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Colon neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ear neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Epiglottic carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastric cancer stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hodgkin's disease mixed cellularity stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intraductal papilloma of breast</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intraductal proliferative breast lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Invasive breast carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage III</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Malignant melanoma in situ</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Metastases to lung</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Metastases to lymph nodes</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neoplasm skin</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neuroendocrine carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Plasmacytoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal cell carcinoma recurrent</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thyroid adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thyroid cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Uterine cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cerebral infarction</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cerebellar infarction</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Movement disorder</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cerebral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Monoparesis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Brain stem infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Carpal tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Complex regional pain syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dyskinesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Facial paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Generalised tonic-clonic seizure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gliosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intercostal neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intracranial venous sinus thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lacunar infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nerve root compression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Orthostatic intolerance</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Paraplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Partial seizures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Post polio syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal cord ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thalamic infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Toxic encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vertebral artery dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Delivery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ectopic pregnancy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device dislocation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Device breakage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Panic reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tobacco abuse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ureterolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urinary tract obstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bladder diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bladder stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Calculus urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal artery arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Stress urinary incontinence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ureteric stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urinary tract inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Menstrual disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ovarian adhesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Prostatic dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Alveolitis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Respiratory distress</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rheumatoid lung</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hyperventilation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Interstitial lung disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lung infiltration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary oedema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dyspnoea exertional</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Laryngeal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal septum deviation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Organising pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Paranasal cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pleural fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary hilum mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary mass</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diabetic foot</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pustular psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Decubitus ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Erythema multiforme</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hand dermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lichenoid keratosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lividity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mucocutaneous ulceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Petechiae</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Purpura</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rash vesicular</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin necrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Subcutaneous emphysema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Systemic lupus erythematosus rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urticarial vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Alcohol use</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Foreign travel</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Postmenopause</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Hospitalisation</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Knee arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Elective surgery</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthrodesis</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hip arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Synovectomy</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Foot operation</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bunion operation</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cholecystectomy</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Surgery</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Therapy change</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rehabilitation therapy</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Laparoscopic surgery</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal operation</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Coronary arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intervertebral disc operation</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteosynthesis</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Osteotomy</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Antibiotic therapy</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthroscopic surgery</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Coronary artery bypass</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Knee operation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rheumatoid nodule removal</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Antibiotic prophylaxis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aortic valve replacement</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bursa removal</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker insertion</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ankle arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Baker's cyst excision</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cataract operation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fracture treatment</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal stone removal</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rotator cuff repair</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Shoulder operation</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal fusion surgery</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thyroidectomy</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abscess drainage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ankle operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Breast conserving surgery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cancer surgery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cardiac operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Coronary angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Emergency care</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gallbladder operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haematoma evacuation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hysterectomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint surgery</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Meniscus operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pain management</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Shoulder arthroplasty</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sigmoidectomy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin graft</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin neoplasm excision</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal decompression</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Stent placement</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tendon operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Toe operation</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arterial stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Breast reconstruction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cardiac ablation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Carpal tunnel decompression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cartilage operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chemotherapy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastrectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hip surgery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infiltration anaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint dislocation reduction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Massage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Mastectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Medical device removal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Open reduction of fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ovarian cystectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Postoperative care</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Prostatic operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pulmonary resection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Radiotherapy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Removal of internal fixation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tendon sheath incision</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tenoplasty</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thyroid operation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Transurethral prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ureteral stent insertion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound treatment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Abdominal hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Adhesiolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Adrenocortical steroid therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Angioplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Antiallergic therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Anticoagulant therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Appendicectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arterial aneurysm repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arterial bypass operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arterial catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arthrotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bone operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bronchial lesion excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Bursal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cardiac pacemaker replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cerebrovascular operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Chest wall operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Coronary revascularisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cryotherapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Cyst removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Debridement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus management</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Eye operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Femoral hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fistula repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fluid replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Fracture debridement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Frontal sinus operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gastric operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Gingival operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haemostasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Injection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Intestinal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Jaw operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint debridement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint injection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Joint stabilisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Laparotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Leg amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ligament operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Limb operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lip repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lithotripsy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lung transplant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lymphoma operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Meniscus removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nephrectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nephroplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nephrostomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Neurectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Oophorectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ossiculoplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ostectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pancreatic operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Parotidectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Percutaneous coronary intervention</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peritoneal lavage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pharyngeal operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pyeloplasty</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Radical prostatectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Radioactive iodine therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Rectal polypectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Renal artery stent placement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Resuscitation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Skin lesion removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Spinal cord operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Sternotomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Therapeutic embolisation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thrombolysis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Toe amputation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tongue operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Transfusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Tumour excision</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Umbilical hernia repair</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Unevaluable therapy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ureterectomy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Ureteric operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Urinary incontinence surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Varicose vein operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Venous operation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vertebral body replacement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound closure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wound drainage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Wrist surgery</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peripheral arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aortic aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Vasculitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Aortic dilatation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arterial occlusive disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Lymphatic fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Microembolism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Pelvic venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peripheral artery aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peripheral artery occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Shock haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Venous thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Venous thrombosis limb</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_vocab>MedDRA v20.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="831" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" subjects_affected="213" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="177" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="137" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="130" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="106" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="7229"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" subjects_affected="79" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Therapy cessation</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="7229"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>AbbVie requests that any investigator or institution that plans on presenting/publishing results disclosure, provide written notification of their request 60 days prior to their presentation/publication. AbbVie requests that no presentation/publication will be instituted until 12 months after a study is completed, or after the first presentation/publication whichever occurs first. A delay may be proposed of a presentation/publication if AbbVie needs to secure patent or proprietary protection.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Global Medical Services</name_or_title>
      <organization>AbbVie (prior sponsor Abbott)</organization>
      <phone>800-633-9110</phone>
      <email>abbvieclinicaltrials@abbvie.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

